| アブストラクト | We aimed to estimate the risk of varied antifungal therapy with azoles causing the syndrome of acquired apparent mineralocorticoid excess (AME) in real-world practice. First, we conducted a disproportionality analysis based on data from the FDA Adverse Event Reporting System (FAERS) database to characterize the signal differences of triazoles-related AME. Second, a systematic review was conducted, and clinical features of AME cases reported in clinical practice were described. In the FAERS database, we identified 27 cases of triazoles-AME, posaconazole [ROR = 865.37; 95%CI (464.14; 1613.45)], and itraconazole [ROR = 556.21; 95% (303.05; 1020.85)] significantly increased the risk of AME events, while fluconazole, voriconazole, and isavuconazole did not affect any of the mineralocorticoid excess targets. Eighteen studies with 39 cases raised evidence of AME following posaconazole and itraconazole treatment, and another 27 cases were identified by analysis of the description of clinical features in the FAERS database. The average age of 66 patients was 55.5 years (6-87 years). AME mainly occurs in patients with posaconazole concentrations above 3 mug/mL (mean = 4.4 mug/mL, range 1.8 approximately 9.5 mug/mL), and is less likely to occur when levels are below 2 mug/mL (6%). The median time to event onset was 11.5 weeks, and 50% of the adverse events occurred within 3 months for posaconazole. The presented study supports very recent findings that posaconazole and itraconazole, but not the other three azole antifungals investigated, are associated with AME and that the effects are dose-dependent, which allows for a dose de-escalation strategy and for substitution with fluconazole, isavuconazole, or voriconazole to resolve the adverse effects. |
|---|
| ジャーナル名 | Antimicrobial agents and chemotherapy |
|---|
| 投稿日 | 2021/10/19 |
|---|
| 投稿者 | Ji, Huan-Huan; Tang, Xue-Wen; Zhang, Ni; Huo, Ben-Nian; Liu, Ying; Song, Lin; Jia, Yun-Tao |
|---|
| 組織名 | Department of Pharmacy, Children's Hospital of Chongqing Medical University,;National Clinical Research Center for Child Health and Disorders, Ministry of;Education Key Laboratory of Child Development and Disorders, Chongqing Key;Laboratory of Pediatrics, Chongqing, China.;Chengdu Shuchuang Linyan Technology Co., Ltd, Chengdu, China.;Department of Pharmacy, National Center for Children's Health, Beijing Children's;Hospital, Capital Medical University, Beijing, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34662186/ |
|---|
